Can Vyvanse Be Added to Wellbutrin in This Patient?
Yes, Vyvanse (lisdexamfetamine) can be added to Wellbutrin (bupropion) in this 23-year-old male with ADHD, PTSD, and anxiety, though the combination requires careful monitoring for anxiety exacerbation and should be initiated at lower doses with gradual titration.
Rationale for Combination Therapy
The available guideline evidence explicitly addresses this combination. There are no studies of the combination of bupropion and stimulants in the treatment of ADHD or other psychiatric conditions. The PDR does not warn against interactions between bupropion and stimulants, and no case reports of side effects when these agents were combined could be located 1. However, the guideline recommends clinicians "proceed with caution in combining these agents until further studies are available" 1.
Treatment Algorithm for ADHD with Comorbid Anxiety and PTSD
Step 1: Prioritize ADHD Treatment with Stimulants
The guideline evidence supports proceeding with stimulant trials even in patients with comorbid anxiety. Data on treatment of comorbid anxiety disorder in ADHD shows that patients with ADHD and comorbid anxiety actually had better treatment responses in the MTA study 1. Early concerns that ADHD patients with comorbid anxiety had less robust responses to stimulants have not been replicated in more extensive clinical trials 1.
The clinician should proceed with a stimulant trial 1. If the stimulant improves ADHD symptoms but anxiety remains problematic, psychosocial interventions should be pursued first, followed by consideration of adding an SSRI if anxiety is severe or non-responsive 1.
Step 2: Specific Considerations for This Patient
Bupropion as baseline therapy: This patient is already on bupropion, which has modest efficacy for ADHD (SMD=-0.32) 2 and may provide some benefit for both PTSD and anxiety symptoms. Recent evidence suggests bupropion may reduce PTSD symptom severity 3 and can have anxiolytic effects in some patients, though it can also provoke anxiety at higher doses 4.
Lisdexamfetamine advantages: Vyvanse has the highest efficacy among ADHD medications (SMD=-1.28) 2 and has a lower abuse potential due to its prodrug formulation 5. The FDA label confirms it is approved for ADHD in adults 6.
Practical Implementation Strategy
Initiation Protocol:
- Start Vyvanse at 30 mg daily (lower end of dosing range) 6
- Continue current Wellbutrin dose unchanged initially
- Monitor closely for anxiety exacerbation, particularly in the first 2-4 weeks
Titration:
- If tolerated after 1 week, may increase to 40 mg
- Maximum dose 70 mg, but titrate slowly given anxiety comorbidity 6
- The FDA label indicates dosing from 30-70 mg for ADHD in adults 6
Monitoring Parameters:
- Anxiety symptoms: Watch for increased restlessness, insomnia, or panic symptoms (common stimulant side effects include anxiety) 1
- PTSD symptoms: Monitor for any worsening of hyperarousal or re-experiencing symptoms
- Blood pressure and heart rate: Check regularly as both medications can increase these parameters 6
- Appetite and sleep: Common side effects include decreased appetite and insomnia 1
Critical Safety Considerations
Cardiovascular Screening:
The FDA label emphasizes checking for heart problems before starting Vyvanse, as sudden death has occurred in patients with heart defects or serious heart disease 6. Obtain a thorough cardiac history including family history of sudden death.
Mental Health Monitoring:
The FDA label warns about new or worsening psychiatric problems including anxiety, psychotic symptoms, or manic symptoms 6. Given this patient's baseline anxiety and PTSD, establish clear symptom thresholds for dose reduction or discontinuation.
Substance Use Risk:
While not mentioned in this case, the FDA label emphasizes that Vyvanse is a Schedule II controlled substance with abuse potential 6. However, evidence suggests lisdexamfetamine may actually reduce cravings in patients with stimulant use history 5.
Expected Outcomes
Based on available evidence:
- ADHD symptoms: Should see significant improvement (78% response rate in adults) 1
- Anxiety: May remain stable or improve if anxiety was secondary to ADHD-related impairment 1. However, monitor for stimulant-induced anxiety exacerbation 7
- PTSD: Bupropion may continue providing benefit 3; stimulants do not have direct evidence for PTSD but reducing ADHD-related functional impairment may indirectly help
Common Pitfalls to Avoid
- Starting at too high a dose: Begin at 30 mg, not 50-70 mg, given anxiety comorbidity
- Inadequate monitoring: Schedule follow-up within 1-2 weeks of initiation, not waiting a month
- Premature discontinuation: Some initial anxiety or activation may resolve after 1-2 weeks; don't abandon treatment immediately unless severe
- Ignoring the PTSD: Ensure patient has appropriate trauma-focused therapy; medications alone are insufficient for PTSD 8
The combination is reasonable and supported by guideline evidence showing no contraindication, though it requires vigilant monitoring for anxiety worsening and cardiovascular effects 1, 6.